Research ArticleArticle
Biodistribution and Metabolism Studies of Lipid Nanoparticle–Formulated Internally [3H]-Labeled siRNA in Mice
Jesper Christensen, Karine Litherland, Thomas Faller, Esther van de Kerkhof, François Natt, Jürg Hunziker, Julien Boos, Iwan Beuvink, Keith Bowman, Jeremy Baryza, Mike Beverly, Chandra Vargeese, Olivier Heudi, Markus Stoeckli, Joel Krauser and Piet Swart
Drug Metabolism and Disposition March 2014, 42 (3) 431-440; DOI: https://doi.org/10.1124/dmd.113.055434
Jesper Christensen
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Karine Litherland
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Thomas Faller
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Esther van de Kerkhof
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
François Natt
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Jürg Hunziker
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Julien Boos
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Iwan Beuvink
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Keith Bowman
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Jeremy Baryza
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Mike Beverly
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Chandra Vargeese
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Olivier Heudi
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Markus Stoeckli
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Joel Krauser
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)
Piet Swart
Drug Metabolism and Pharmacokinetics (J.C., K.L., T.F., E.v.d.K., O.H., J.K., P.S.), Analytical Sciences (M.S.), and Biologics Center (F.N., J.H., J.Bo., I.B.), Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland; and Biologics Center, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (K.B., J.B., M.B., C.V.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
ADME Properties of LNP-Formulated [3H]-siRNA
Jesper Christensen, Karine Litherland, Thomas Faller, Esther van de Kerkhof, François Natt, Jürg Hunziker, Julien Boos, Iwan Beuvink, Keith Bowman, Jeremy Baryza, Mike Beverly, Chandra Vargeese, Olivier Heudi, Markus Stoeckli, Joel Krauser and Piet Swart
Drug Metabolism and Disposition March 1, 2014, 42 (3) 431-440; DOI: https://doi.org/10.1124/dmd.113.055434
Research ArticleArticle
ADME Properties of LNP-Formulated [3H]-siRNA
Jesper Christensen, Karine Litherland, Thomas Faller, Esther van de Kerkhof, François Natt, Jürg Hunziker, Julien Boos, Iwan Beuvink, Keith Bowman, Jeremy Baryza, Mike Beverly, Chandra Vargeese, Olivier Heudi, Markus Stoeckli, Joel Krauser and Piet Swart
Drug Metabolism and Disposition March 1, 2014, 42 (3) 431-440; DOI: https://doi.org/10.1124/dmd.113.055434
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement